Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis

Oscar L. Alves, Aiden J. Doyle, Tobias Clausen, Charlotte Gilman, Ross Bullock

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Despite recent advances in our understanding of human traumatic brain injury (TBI) pathophysiology, we still need effective neuroprotective agents. The lack of rigorous drug pharmacokinetlc studies in the "living" brain is an important cause of neuroprotection trials failure in human TBI research. In the past, several drugs have been labeled as inefficient, and even withdrawn from expensive trials, without knowing their actual penetration in the traumatized human brain. The injured brain is characterized by an increased diffusion distance, due to edema, and reduced blood flow that modulates drug transport across the blood-brain barrier (BBB). In the study reported in this paper, we used cerebral microdialysis to provide a safe and efficient tool for continuous in vivo evaluation of bioavailability and pharmacologic efficacy of topiramate, a glutamate release inhibitor. Topiramate crossed the BBB in neuroprotective concentrations, and showed a lowering effect on glutamate levels, thereby modifying the natural history of glutamate release after TBI. The use of cerebral microdialysis in phase II drug studies will allow the detection of the appropriate therapeutic window and dosage for the neuroprotective agent. This strategy represents a clear improvement compared to traditional clinical trial design, and will reduce the trial costs.

Original languageEnglish
Pages (from-to)25-34
Number of pages10
JournalAnnals of the New York Academy of Sciences
Volume993
StatePublished - Jul 16 2003
Externally publishedYes

Fingerprint

Microdialysis
Neuroprotective Agents
Brain
Glutamic Acid
Blood-Brain Barrier
Pharmaceutical Preparations
Natural History
Biological Availability
Edema
Clinical Trials
Costs and Cost Analysis
topiramate
Traumatic Brain Injury
Evaluation
Blood
Research
Drugs
Costs
Therapeutics

Keywords

  • Clinical trials
  • Microdialysis
  • Neuroprotection
  • Severe TBI
  • Topiramate

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Alves, O. L., Doyle, A. J., Clausen, T., Gilman, C., & Bullock, R. (2003). Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis. Annals of the New York Academy of Sciences, 993, 25-34.

Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis. / Alves, Oscar L.; Doyle, Aiden J.; Clausen, Tobias; Gilman, Charlotte; Bullock, Ross.

In: Annals of the New York Academy of Sciences, Vol. 993, 16.07.2003, p. 25-34.

Research output: Contribution to journalArticle

Alves, OL, Doyle, AJ, Clausen, T, Gilman, C & Bullock, R 2003, 'Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis', Annals of the New York Academy of Sciences, vol. 993, pp. 25-34.
Alves, Oscar L. ; Doyle, Aiden J. ; Clausen, Tobias ; Gilman, Charlotte ; Bullock, Ross. / Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis. In: Annals of the New York Academy of Sciences. 2003 ; Vol. 993. pp. 25-34.
@article{ef7e58372f2f497e945bdf07bf25f644,
title = "Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis",
abstract = "Despite recent advances in our understanding of human traumatic brain injury (TBI) pathophysiology, we still need effective neuroprotective agents. The lack of rigorous drug pharmacokinetlc studies in the {"}living{"} brain is an important cause of neuroprotection trials failure in human TBI research. In the past, several drugs have been labeled as inefficient, and even withdrawn from expensive trials, without knowing their actual penetration in the traumatized human brain. The injured brain is characterized by an increased diffusion distance, due to edema, and reduced blood flow that modulates drug transport across the blood-brain barrier (BBB). In the study reported in this paper, we used cerebral microdialysis to provide a safe and efficient tool for continuous in vivo evaluation of bioavailability and pharmacologic efficacy of topiramate, a glutamate release inhibitor. Topiramate crossed the BBB in neuroprotective concentrations, and showed a lowering effect on glutamate levels, thereby modifying the natural history of glutamate release after TBI. The use of cerebral microdialysis in phase II drug studies will allow the detection of the appropriate therapeutic window and dosage for the neuroprotective agent. This strategy represents a clear improvement compared to traditional clinical trial design, and will reduce the trial costs.",
keywords = "Clinical trials, Microdialysis, Neuroprotection, Severe TBI, Topiramate",
author = "Alves, {Oscar L.} and Doyle, {Aiden J.} and Tobias Clausen and Charlotte Gilman and Ross Bullock",
year = "2003",
month = "7",
day = "16",
language = "English",
volume = "993",
pages = "25--34",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis

AU - Alves, Oscar L.

AU - Doyle, Aiden J.

AU - Clausen, Tobias

AU - Gilman, Charlotte

AU - Bullock, Ross

PY - 2003/7/16

Y1 - 2003/7/16

N2 - Despite recent advances in our understanding of human traumatic brain injury (TBI) pathophysiology, we still need effective neuroprotective agents. The lack of rigorous drug pharmacokinetlc studies in the "living" brain is an important cause of neuroprotection trials failure in human TBI research. In the past, several drugs have been labeled as inefficient, and even withdrawn from expensive trials, without knowing their actual penetration in the traumatized human brain. The injured brain is characterized by an increased diffusion distance, due to edema, and reduced blood flow that modulates drug transport across the blood-brain barrier (BBB). In the study reported in this paper, we used cerebral microdialysis to provide a safe and efficient tool for continuous in vivo evaluation of bioavailability and pharmacologic efficacy of topiramate, a glutamate release inhibitor. Topiramate crossed the BBB in neuroprotective concentrations, and showed a lowering effect on glutamate levels, thereby modifying the natural history of glutamate release after TBI. The use of cerebral microdialysis in phase II drug studies will allow the detection of the appropriate therapeutic window and dosage for the neuroprotective agent. This strategy represents a clear improvement compared to traditional clinical trial design, and will reduce the trial costs.

AB - Despite recent advances in our understanding of human traumatic brain injury (TBI) pathophysiology, we still need effective neuroprotective agents. The lack of rigorous drug pharmacokinetlc studies in the "living" brain is an important cause of neuroprotection trials failure in human TBI research. In the past, several drugs have been labeled as inefficient, and even withdrawn from expensive trials, without knowing their actual penetration in the traumatized human brain. The injured brain is characterized by an increased diffusion distance, due to edema, and reduced blood flow that modulates drug transport across the blood-brain barrier (BBB). In the study reported in this paper, we used cerebral microdialysis to provide a safe and efficient tool for continuous in vivo evaluation of bioavailability and pharmacologic efficacy of topiramate, a glutamate release inhibitor. Topiramate crossed the BBB in neuroprotective concentrations, and showed a lowering effect on glutamate levels, thereby modifying the natural history of glutamate release after TBI. The use of cerebral microdialysis in phase II drug studies will allow the detection of the appropriate therapeutic window and dosage for the neuroprotective agent. This strategy represents a clear improvement compared to traditional clinical trial design, and will reduce the trial costs.

KW - Clinical trials

KW - Microdialysis

KW - Neuroprotection

KW - Severe TBI

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=0038727791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038727791&partnerID=8YFLogxK

M3 - Article

C2 - 12853292

AN - SCOPUS:0038727791

VL - 993

SP - 25

EP - 34

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -